1health has partnered with Apollo Health Group to bring Apollo’s specialized high performing NGS tests, such as hereditary cancer genetic screenings (CGx) and pharmacogenetics screenings (PGx) to the broader clinical market.
With 1health, Apollo Health Group is streamlining complex genetic testing workflows and eliminating error-prone paper-based processes. Now, using 1health’s online portal, physicians located anywhere across the United States can sign up and place orders digitally and securely and process test results quickly and safely.
“With 1health’s technology, we are fundamentally changing the way people at risk of cancer and genetic disorders are able to get tested. We have simplified a highly complex process and made it repeatable. Now cancer genetics and pharmacogenetics tests can be ordered in minutes online by any U.S. physician. The results are that people will get faster treatment and lives will be saved,” stated Apollo Health Group COO, Blaine Smith. “In addition, we were up and running in 30 days – which is an incredibly fast timeline for a project with this scope,” added Smith.
What is even more powerful to understand is that now, through Apollo Health Group, these specialized tests can be ordered by physicians located anywhere across the U.S. It enables Apollo to extend its market reach and help hundreds of thousands of people get access to these genetic tests, saving lives.
“1health has made an incredibly complex process that includes multi-page patient questionnaires, sophisticated physician diagnosis reports, and laborious insurance documentation easy, fast, and secure,” states Mehdi Maghsoodnia, Chief Executive Officer of 1health. “What is even more powerful to understand is that now, through Apollo Health Group, these specialized tests can be ordered by physicians located anywhere across the U.S. It enables Apollo to extend its market reach and help hundreds of thousands of people get access to these genetic tests,” added Maghsoodnia.
Predictive genetic testing helps a physician understand how a person’s genetic composition may affect the body’s response to medications and/or how inherited gene mutations might put a person at risk of getting cancer.
The predictive genetic testing market is forecast to grow at 13.9% CAGR and reach USD 3.4 billion by 2027, according to The Market Research Future Report1.
To read the press release click HERE
Why the Right PGx Launch Strategy Will Save You Money, Time, and Resources
The field of CGx and PGx has grown leaps and bounds in the last 30 years. While the road ahead may be full of promises...
Share with Your Patients, Providers, and Peers on How PGx Improves Patient Outcome
As advancement in PGx testing gains wider traction, the strength of PGx testing for laboratories as a growth opportunity in 2023 and beyond cannot be...
Inspire Wellness@Home launches Health and Wellness Lab Tests DTC in partnership with 1health.io
1health partners with Inspire Wellness@Home to bring health and wellness tests, such as inflammation, sleep and stress to heart health and thyroid to the broader…
Dante Genomics launches advance genome testing in partnership with 1health.io
Dante Genomics uses the 1health.io platform to accelerates their go to market and expand availability in all 50 states using the 1health online prescription services
Patients Choice Labs selects 1health to Launch Genetic Testing to Consumers
With 1health.io technology, Patients Choice Laboratories customers will be able to order tests online